BONE FORMATION-RESORPTION COUPLING AND OSTEOPOROSIS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 PTH治疗增加骨形成和脊柱、髋部和全身BMD，但降低皮质BMD并引起血钙短暂小幅升高。 为了改善治疗，并了解PTH增加骨形成的方式，本研究比较了PTH，PTH+阿仑膦酸钠和阿仑膦酸钠治疗男性和绝经后女性骨质疏松症30个月。为了评估停用PTH对骨转换和BMD的影响，在有和无阿仑膦酸钠的情况下，没有参与者在30-42个月期间服用PTH，但服用阿仑膦酸钠的人继续服用。在42-54个月期间，他们也继续服用阿仑膦酸钠，所有患者都服用PTH。 第42-54个月测试PTH对骨形成的积极作用，在治疗1-2年后减弱，在12个月的假期后恢复全面。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. PTH treatment increases bone formation and spine, hip and total body BMD, but reduces cortical BMD and causes transient small increases in blood calcium. To improve treatment, and insight into the ways PTH increases bone formation, this study compare PTH, PTH+alendronate, and alendronate treatment of osteoporosis in men and postmenopausal women for 30 months. To assess the effects of stopping PTH on bone turnover and BMD, in both the presence and absence of alendronate, no participants take PTH during months 30-42, but those who took alendronate continue it. During months 42-54 they also continue alendronate, and all patients take PTH. Months 42-54 test whether PTH's positive effects on bone formation, which wane after 1-2 years of therapy, resume in full force after a 12 month holiday off PTH.